Nuclivision provides novel radiotracers and treatments for oncology to help patients by improving the safety of nuclear medicine.
Nuclivision has raised $5.7M in total funding. The most recent round was Seed. The last funding was announced in April 2025.
Nuclivision's investors include LUMO labs, HERAN Partners, imec.istart Future Fund, Lumiares.
Nuclivision is headquartered in Ghent, Belgium.
Nuclivision provides novel radiotracers and treatments for oncology to help patients by improving the safety of nuclear medicine.
Nuclivision is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nuclivision — Funding & Investors." VCBacked, April 24, 2025, https://www.vcbacked.co/company/nuclivision. Accessed August 14, 2026.
VCBacked. (2025). Nuclivision — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nuclivision
{{cite web |title=Nuclivision — Funding & Investors |url=https://www.vcbacked.co/company/nuclivision |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated